Dr. Ko-Jiunn Liu — Patent

PATENTS
  1. ANTIBODIES AGAINST INFECTIOUS DISEASES (US 10766951B2, 2020/9/8-2036/4/4)(ROC I708784, 2020/11/1-2036/3/31)
  2. 提昇及抑制免疫調節細胞表現之方法 (ROC I693943, 2020/5/21)(China 2021/2/1)
  3. Methods to Upregulate and Suppress an Expression of Immunomodulatory Cells.  (EU. 2019/12/25)
  4. ANTIBODIES SPECIFIC TO ALPHA-ENOLASE AND USES THEREOF (JP 6577669, 2019/7/17~2038/3/15)
  5. Alpha-enolase Specific Antibodies and Method of Use in Immune Diseases.  (US 9750804, 2017/9/5-2033/12/19)(EP 3082863, 2019/4/17~2034/12/21)(AU 2014368857, 2020/5/21-2033/12/19)
  6. 人源化α-烯醇化酶特異性抗體及其於癌症治療之應用 (ROC I579304, 2017/4/21-2035/12/29).
  7. α-烯醇化酶特異性抗體及其使用在免疫疾病之方法 (ROC I572358, 2017/3/1-2034/12/17).
  8. Humanized Alpha-enolase Specific Antibodies and Methods of Uses in Cancer Therapy (US 9527922 B2, 2016/12/27-2034/12/30)(JP 6585721, 2019/10/2~2034/12/30)
  9. α-烯醇化酶特異性抗體及其於癌症治療之應用  (ROC I549967, 2016/9/21-2034/12/16)
  10. Alpha-enolase Specific Antibodies and Method of Use in Cancer Therapy (US 9382331 B2, 2016/7/5-2033/12/26)(RU 2656153, 2018/5/31-2033/12/19)(EP 3083697, 2019/4/17-2034/12/19)(AU 2013408259, 2020/5/21-2033/12/19)
  11. Method for the diagnosis of the presence of an ovarian cancer (US 9200262 B2, 2015/12/1)
  12. 製備免疫調節細胞之方法、依該方法所製備之細胞及其應用. (ROC I486449, 2015/6/1)
  13. 診斷及治療 α-異烯醇酶(α-enolase)相關疾病之抗-α-異烯醇酶抗體. (ROC I468176, 2015/01/11-2030/01/27)
  14. Method for Generating Immunomodulatory Cells, The Cells Prepared Therefrom, and Use Thereof  (US 8927278B2.  2015/1/6) (China 1020028CN))
  15. Anti-alpha-Enolase I Antibodies for Diagnosis and Treatment of alpha-Enolase-I-Associated Diseases (US 8449881B2, 2013/5/28)
  16. An Antigen Polypeptide for the Diagnosis and/or Treatment of Ovarian Cancer (US 7928188B2, 2011/4/19)
  17. Alpha-enolase Specific Antibody and Method of Use (US 7645453B2, 2010/1/12-2026/12/29)
  18. α-烯醇酶特異性抗體及其應用方法 (ROC I304443, 2008/12/21-2026/12/25)
Technology transfer/sub-license

Technology transfer of “Humanized anti-alpha-enolase antibody for the treatment of cancer, multiple sclerosis, rheumatoid arthritis, and sepsis” to Development Center for Biotechnology on January 2, 2014, and sub-license of “Development of anti-ENO1 monoclonal antibody drug” to 上毅生物科技股份有限公司on October 27, 2015.

Share Button

Comments are closed.